[{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Neurology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Suffield Research Centre","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Neurology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ Suffield Research Centre","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Suffield Research Centre"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Defence R&D Canada","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Neurology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ Defence R&D Canada","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Defence R&D Canada"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"||Glutathione","graph1":"Neurology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Canaccord Genuity"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Delta Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Delta Health","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Delta Health"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"EMD Financial","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ EMD Financial","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ EMD Financial"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ University of California","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ University of California"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Microneedle Patch","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Collaboration","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Microneedle Patch","sponsorNew":"Revive Therapeutics \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ PharmaTher"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"University Of Health Sciences Antigua","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Revive Therapeutics \/ University Of Health Sciences Antigua","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ University Of Health Sciences Antigua"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Patch","sponsorNew":"Revive Therapeutics \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ PharmaTher"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"University of Wisconsin","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ University of Wisconsin","highestDevelopmentStatusID":"6","companyTruncated":"Revive Therapeutics \/ University of Wisconsin"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"DRDC","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Neurology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ DRDC","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ DRDC"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"DRDC","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Neurology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revive Therapeutics \/ DRDC","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ DRDC"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"University of Wisconsin","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Revive Therapeutics \/ University of Wisconsin","highestDevelopmentStatusID":"6","companyTruncated":"Revive Therapeutics \/ University of Wisconsin"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Hampton Securities Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Hampton Securities Limited","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Hampton Securities Limited"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Attwill Medical Solutions","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revive Therapeutics \/ Attwill Medical Solutions","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Attwill Medical Solutions"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Oncology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Revive Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
